Core Insights - Elite Pharmaceuticals, Inc. (ELTP) has experienced a significant decline in stock price, losing 10.7% since its earnings report for the quarter ended December 31, 2025, compared to a 0.2% gain in the S&P 500 Index during the same period [1] Financial Performance - For Q3 fiscal 2026, Elite Pharmaceuticals reported total revenues of $31.6 million, a 119.9% increase from $14.4 million in the same quarter last year [2] - Manufacturing fees rose by 128.4% to $31.4 million from $13.7 million, while licensing fees fell by 67.2% to $0.2 million from $0.6 million [2] - Gross profit increased by 111.7% year over year to $12.9 million from $6.1 million, with a gross margin of 41%, slightly down from 43% in the prior-year period [2] Operating Expenses and Income - Operating expenses decreased by 21.5% year over year to $3.9 million from $5 million, attributed to lower research and development and general administrative costs [3] - Income from operations surged to $9 million from $1.1 million in the prior-year quarter, while net income reached $18.6 million compared to a net loss of $10.9 million a year earlier [3] - On a per-share basis, ELTP earned $0.01 against a loss of $0.01 in the prior-year quarter [3] Business Segments - Elite Pharmaceuticals operates in a single reportable segment focused on ANDA (generic) products, generating operating income of $11.9 million in the quarter, up from $4.3 million a year earlier [4] Year-to-Date Performance - For the first nine months of fiscal 2026, revenue totaled $108.1 million, up from $52 million in the comparable period last year [5] - Gross profit for the nine-month period rose to $54.3 million from $22.8 million, and income from operations increased to $38.9 million from $8.4 million [5] - Operating cash flow improved significantly to $14.6 million for the nine months ended December 31, 2025, from $3.5 million in the prior-year period [5] Balance Sheet Strength - The balance sheet strengthened, with cash rising to $21.1 million as of December 31, 2025, from $11.3 million as of March 31, 2025 [6] - Working capital improved to $83.6 million as of December 31, 2025, from $45.9 million as of March 31, 2025 [6] Management Commentary - Management attributed revenue and profit growth to strong sales of recently launched Elite-label generics and broader product portfolio expansion [7] - The company has transitioned into a larger-scale generic supplier, with increased market penetration and customer reach as key drivers of improved financial performance [7] Margin Insights - Management noted that the gross margin dip compared to the year-ago quarter was due to a higher proportion of indirect sales through wholesalers, which typically carry lower margins [8] - Certain one-time costs related to new product introductions did not recur in the December period, impacting earlier quarters [8] Research and Development - Research and development expenses declined by 41.9% year over year to $1 million in the quarter from $1.8 million, reflecting a shift in resource allocation [9] - General and administrative expenses also decreased by 9.5% year over year to $2.5 million from $2.7 million [9] Strategic Priorities - While no formal quantitative guidance was provided, management expressed confidence in fiscal 2026 being the strongest year to date, with year-to-date revenue already exceeding prior full-year results [11] - The company highlighted continued investment in research and development, additional ANDA filings, and potential merger and acquisition opportunities as strategic priorities [11] - Management is also evaluating uplisting alternatives should suitable M&A opportunities not materialize [11] Recent Developments - During the quarter, Elite Pharmaceuticals expanded its generic portfolio, receiving FDA approval in November 2025 for a generic version of Ropinirole Extended-Release Tablets [12] - Earlier asset acquisitions included approved ANDAs for products such as Methadone Hydrochloride Tablets under an agreement with Nostrum Laboratories [12]

Core Viewpoint - Elite Pharmaceuticals is conducting its Third Quarter of Fiscal Year 2026 Conference Call, indicating a focus on discussing financial performance and future expectations [1]. Group 1: Company Overview - The conference call is hosted by Mr. Nasrat Hakim, the President and CEO of Elite Pharmaceuticals, who will lead the discussion on the company's performance and outlook [4]. Group 2: Forward-Looking Statements - Elite Pharmaceuticals has issued a reminder that the remarks made during the call may contain forward-looking statements that involve risks and uncertainties, which are subject to change [2]. - The company emphasizes that actual results may differ materially from those anticipated in forward-looking statements, and it disclaims any obligation to update or revise these statements except as required by law [3].

Northvale, New Jersey--(Newsfile Corp. - February 17, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced results for the third quarter of fiscal year 2026, the three months ended December 31, 2025 ("Third Quarter").Consolidated revenues for the three-month period ending December 31, 2025, were $31.6 million, an increase of $17.2 million or approximately 120% as compared to the comparable period of the ...

Northvale, New Jersey--(Newsfile Corp. - February 11, 2026) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced today that the third quarter financial results of the 2026 fiscal year will be released on Tuesday, February 17, 2026. Elite's management will host a live conference call on Wednesday, February 18th, at 11:30 AM EST to discuss the company's financial and operating results and provide a general busi ...

Core Viewpoint - Elite Pharmaceuticals, Inc. (ELTP) has experienced significant revenue growth driven by the launch of its lisdexamfetamine product line, despite facing challenges from price competition in the generic market [2][7]. Financial Performance - In Q2 of fiscal 2026, Elite Pharmaceuticals reported revenues of $36.3 million, a 92.4% increase from $18.9 million year-over-year, primarily due to the expansion of its lisdexamfetamine product line [2]. - Operating income surged 135.7% year-over-year to $8.2 million from $3.5 million, reflecting improved scale and product mix [2]. - Gross profit increased by 71.7% to $14.1 million from $8.2 million, although margins tightened sequentially due to price competition and one-time wholesaler fees [2]. - The company posted a net income of $13.7 million, translating to earnings of $0.01 per share, compared to a net loss of $11 million or 1 cent per share in the same quarter last year [2]. Research and Development - R&D spending decreased by 29.5% to $1.4 million from $1.9 million year-over-year, attributed to timing rather than reduced investment [3]. General and Administrative Expenses - General and administrative expenses rose 77.2% to $4 million from $2.3 million, driven by increased sales administration needs and compliance requirements [3][8]. Market Position and Product Performance - Elite Pharmaceuticals holds approximately 8% market share in lisdexamfetamine, with 19% in amphetamine immediate-release (IR) and 12% in amphetamine extended-release (ER) [4]. - Smaller marketed products like phendimetrazine achieved a 30% market share, while recently launched products contributed modest volumes [5]. Working Capital and Financial Health - The company ended the quarter with $75.1 million in working capital, up from $45.9 million as of March 31, 2025, supported by strong operating cash flow of $19.9 million over six months [6]. - Elite Pharmaceuticals maintains low and declining debt, enhancing its balance sheet strength [6]. Management Insights - Management noted that year-over-year gains reflect the maturation of the Elite label and the rapid expansion of lisdexamfetamine, which was not part of the previous year's quarter [7]. - The increase in G&A costs is linked to the complexity of handling larger order volumes and compliance across multiple states [8]. Market Dynamics - Competitive pressures in the lisdexamfetamine segment intensified with over 10 manufacturers, leading to price erosion despite increased shipment volumes [10]. - The Drug Enforcement Administration's decision to relax quotas for controlled substances contributed to heightened price competition [10]. Strategic Focus - The company is prioritizing three core product categories: lisdexamfetamine, amphetamine IR, and amphetamine ER, due to their attractive margins [12]. - Elite Pharmaceuticals is shifting towards indirect distribution channels, which broadens market access but may lower margins due to wholesaler fees [11]. Future Outlook - Management anticipates pricing stabilization in the lisdexamfetamine market and continued growth in the generic ADHD market [13]. - Upcoming product launches include ropinirole ER and methadone, with plans to file an ANDA for an undisclosed anticoagulant generic [13]. M&A Activity - Elite Pharmaceuticals is actively evaluating merger and acquisition opportunities, with several potential partners showing interest [14].

Core Insights - Elite Pharmaceuticals, Inc. reported consolidated revenues of $36.3 million for the second quarter of fiscal year 2026, marking an increase of $17.4 million or approximately 92% compared to the same period in the previous fiscal year [2] - Income from operations reached $8.2 million, an increase of $4.7 million or approximately 136% year-over-year, primarily driven by sales of lisdexamfetamine products and strong growth in Elite's product lines [2] Financial Performance - The significant revenue growth of 92% is attributed to the successful launch of new products and overall strong performance in the company's product lines [2] - The increase in income from operations reflects improved operational efficiency and market demand for Elite's niche generic products [2] Conference Call Information - A conference call is scheduled for November 17, 2025, at 11:30 AM EST to discuss the financial results and recent business developments [3][4] - Stakeholders are encouraged to submit questions in advance of the call [3]

Core Insights - Elite Pharmaceuticals, Inc. (ELTP) shares increased by 6.3% following the earnings report for the quarter ended June 30, 2025, outperforming the S&P 500 Index, which saw a 1.1% loss during the same period [1] Financial Performance - ELTP reported first-quarter fiscal 2026 revenues of $40.2 million, a 113.9% increase from $18.8 million year-over-year [2] - Manufacturing fees rose by 115.7% to $39.8 million from $18.4 million, while licensing fees increased by 20.7% to $0.43 million from $0.36 million [2] - Gross profit surged 221.3% to $27.2 million from $8.5 million, driven by a favorable product mix and a higher proportion of direct sales [2] Operating Income and Loss - Operating income was $21.7 million, significantly up from $3.9 million a year earlier, but the company reported a net loss of $5.9 million, or $0.01 per share, compared to a net income of $0.6 million in the previous year [3] - The net loss was primarily due to a non-cash charge of $22.1 million related to the change in fair value of warrant derivative liabilities [7] Operating Expenses and Margins - Operating expenses increased by 19.9% year-over-year to $5.5 million, with general and administrative costs rising by 72.9% to $3.4 million [4] - Research and development spending decreased by 22.6% to $1.7 million due to lower product development activity [4] - Gross margin expanded to 68% from 45%, supported by sales of higher-margin Elite label products [4] Cash Flow and Working Capital - As of June 30, 2025, the company had $21.7 million in cash, up from $11.3 million as of March 31, 2025 [5] - Cash flow from operations was strong, generating $14.8 million during the quarter compared to $3.1 million in the prior year [5] - Working capital improved to $67.1 million from $45.9 million at the end of March 2025, reflecting higher accounts receivable, inventory, and cash balances [5] Management Commentary - Management attributed the strong performance to growth in Elite label product lines and contributions from newly launched lisdexamfetamine products [6] - The company emphasized that recent launches are effectively scaling in the market, contributing to revenue growth and margin expansion [6] Future Guidance - Elite Pharmaceuticals did not provide formal financial guidance for fiscal 2026 but indicated a focus on scaling recently launched generics and transitioning to direct sales under the Elite label [8] Product Developments - The company launched a generic version of Percocet in April 2025 and reported positive bioequivalence study results for a generic anticoagulant in June 2025, paving the way for a potential ANDA filing [10] - These developments enhance ELTP's diverse portfolio of niche generics, including recent introductions like generic Norco and generic Vyvanse [10]

Elite Pharmaceuticals, Inc. Reports Financial Results for the First Quarter of Fiscal Year 2026 ended June 30, 2025 and Provides Conference Call InformationConference Call Scheduled for Friday, August 15 at 11:30 AM EDTAugust 14, 2025 4:24 PM EDT | Source: Elite Pharmaceuticals, Inc.Northvale, New Jersey--(Newsfile Corp. - August 14, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developing niche generic products, announced resu ...

Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss First Quarter 2026 Financial Results on August 15, 2025Financials for First Quarter of Fiscal Year 2026 Ended June 30, 2025 will be released on Thursday, August 14, 2025August 08, 2025 4:30 PM EDT | Source: Elite Pharmaceuticals, Inc.Northvale, New Jersey--(Newsfile Corp. - August 8, 2025) - Elite Pharmaceuticals, Inc. (OTCQB: ELTP) ("Elite" or the "Company"), a specialty pharmaceutical company developi ...